Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online :

Original article / research
Table of Contents - Year : 2013 | Month : September | Volume : 7 | Issue : 9 | Page : 1959 - 1963

Experience with Biodegradable Polymer Coated Sirolimus-Eluting Coronary Stent System in “Real-Life” Percutaneous Coronary Intervention: 24-Month Data from the Manipal-S Registry 1959-1963

Ranjan Shetty, G. Vivek, Ashok Thakkar, Supriya Sunder Mishra, Vivek Joseph, Mithun Gopal Devraj, Anil Tumkur, Umesh Pai

Dr. Ranjan Shetty K.,
Associate Professor, Department of Cardiology, KMC, Manipal-576104, Karnataka, India.
Phone: +91 9243350978, E-mail:

Introduction: Despite the undeniable clinical efficacy of drug-eluting stents with durable polymers, concerns regarding their long-term safety have been raised, especially in more complex subsets. The Manipal-S Registry was designed to evaluate the safety and effectiveness of the biodegradable polymer coated Supralimus® Sirolimus-Eluting Coronary Stent for the treatment of coronary artery disease, across a wide range of patients who are treated in real-life clinical practice.

Methods: All the consecutive 116 patients who underwent single-vessel or multiple vessel percutaneous coronary interventions with the use of Supralimus® sirolimus-eluting stents between September 2009 and December 2010, were included in this study. Patients were clinically followed-up at 1, 9, 12 and 24 months post-procedure. All clinical, procedural, and follow-up information were collected and analysed.

Results: In total 116 patients, 126 lesions were implanted with 144 stents which had an average stent length of 25.8±8.0 mm. The incidences of any major adverse cardiac and cerebral events at 1, 9, 12 and 24 months were 0, 5 (4.3%), 8 (6.9%), and 10 (8.6%) respectively.

Conclusion: These 24-month results clearly provide evidence for safety and effectiveness of the Supralimus® Sirolimus-eluting coronary stent system with the biodegradable polymer in real-life patients, even in those with acute myocardial infarctions.